AUTL - Autolus gains after announcing 100 percent complete remission in blood cancer trial

Autolus Therapeutics ([[AUTL]] +33.3%) has surged today in reaction to impressive results from a Phase 1 trial for its CD19 CAR T cell therapy AUTO1 in relapsed / refractory (r/r) indolent B cell lymphomas ((IBCL)).The data is included in an abstract presentation to be unveiled at the European Hematology Association ((EHA)) scheduled June 9 - 17, 2021.As of February 18, data cutoff ten r/r IBCL patients had received AUTO1, and nine were available for evaluation.As per early data, the patients have achieved 100% complete remission rates and excellent CAR engraftment and expansion, the company said.Eight out of nine patients are in ongoing remission with a median of 3.1 months (range 1-5.6m), and one patient in complete remission has died due to COVID-19.The experimental therapy has demonstrated a tolerable safety profile in patients. Five patients have shown symptoms related to Cytokine Release Syndrome ((CRS)) with four patients and one patient indicating Grade 1

For further details see:

Autolus gains after announcing 100 percent complete remission in blood cancer trial